This HTML5 document contains 9 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

PrefixNamespace IRI
marcrelhttp://id.loc.gov/vocabulary/relators/
dctermshttp://purl.org/dc/terms/
dchttp://purl.org/dc/elements/1.1/
n2https://hal.archives-ouvertes.fr/inserm-03349233#
n8http://www.idref.fr/140218483/
n6http://www.idref.fr/073452149/
bibohttp://purl.org/ontology/bibo/
n7http://www.idref.fr/113205252/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
xsdhhttp://www.w3.org/2001/XMLSchema#
Subject Item
n2:id
marcrel:aut
n6:id n7:id n8:id
dcterms:bibliographicCitation
Kaufman Jonathan, Gasparetto Cristina, Schjesvold Fredrik, Moreau Philippe, Touzeau Cyrille, Facon Thierry, Boise Lawrence, Jiang Yanwen, Yang Xiaoqing, Dunbar Fengjiao, Vishwamitra Deeksha, Unger Stefanie, Macartney Tammy, Pesko John, Yu Yao, Salem Ahmed, Ross Jeremy, Hong Wan‐jen, Maciag Paulo, Pauff James, Kumar Shaji. Targeting BCL ‐2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma. American Journal of Hematology, Wiley, 2021, 96 (4), pp.418 - 427. ⟨10.1002/ajh.26083⟩ Kaufman Jonathan, Gasparetto Cristina, Schjesvold Fredrik, Moreau Philippe, Touzeau Cyrille, Facon Thierry, Boise Lawrence, Jiang Yanwen, Yang Xiaoqing, Dunbar Fengjiao, Vishwamitra Deeksha, Unger Stefanie, Macartney Tammy, Pesko John, Yu Yao, Salem Ahmed, Ross Jeremy, Hong Wan‐jen, Maciag Paulo, Pauff James, Kumar Shaji. Targeting BCL ‐2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma. American Journal of Hematology, 2021, 96 (4), pp.418 - 427. ⟨10.1002/ajh.26083⟩ Kaufman Jonathan, Gasparetto Cristina, Schjesvold Fredrik, Moreau Philippe, Touzeau Cyrille, Facon Thierry, Boise Lawrence, Jiang Yanwen, Yang Xiaoqing, Dunbar Fengjiao, Vishwamitra Deeksha, Unger Stefanie, Macartney Tammy, Pesko John, Yu Yao, Salem Ahmed, Ross Jeremy, Hong Wan‐jen, Maciag Paulo, Pauff James, Kumar Shaji . Targeting BCL ‐2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma . American Journal of Hematology, 2021, 96 (4), pp.418 - 427 . ⟨10.1002/ajh.26083⟩
dcterms:title
Targeting BCL ‐2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma
dc:date
2021
bibo:doi
10.1002/ajh.26083